Technical Analysis for BGNE - BeiGene, Ltd.

Grade Last Price % Change Price Change
grade C 131.49 -4.88% -6.75
BGNE closed down 4.88 percent on Friday, May 17, 2019, on 89 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
1 Watcher
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Flat Up
See historical BGNE trend table...

Date Alert Name Type % Chg
Overbought Stochastic Strength 0.00%
MACD Bullish Centerline Cross Bullish -4.88%
NR7 Range Contraction -4.88%
NR7-2 Range Contraction -4.88%
Stochastic Reached Overbought Strength -4.88%
Above Upper BB Strength -4.88%
Gapped Up Strength -4.88%
Overbought Stochastic Strength -4.88%
Upper Bollinger Band Touch Strength -4.88%
50 DMA Support Bullish -1.47%

Older signals for BGNE ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Read My Charts!
Configure default chart indicators
Basic chart:

Profile
BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops various oncology drugs in the People's Republic of China. The company's clinical stage drug candidates include BGB-3111, a small molecule BTK inhibitor for the treatment of various lymphomas; BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations; BGB-290, an inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; and BGB-A317, a humanized monoclonal antibody for solid-organ and blood-borne cancers. Its preclinical programs comprise a PD-L1 monoclonal antibody, an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications. The company was founded in 2010 and is based in Camana Bay, Cayman Islands.
Biopharmaceutical Cancers Monoclonal Antibodies Oncogenes Humanized Antibody Lymphomas Ras Subfamily Braf Kras
Is BGNE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 1 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
May 16 BeiGene Announces Clinical Data on Tislelizumab and Zanubrutinib to be Presented at the 24th Congress of the European Hematology Association
May 13 72 Biggest Movers From Friday
May 10 BRIEF-Beigene Posts Qtrly Net Loss Attributable Of $167.6 Million
May 9 BeiGene Q1 revenues up 139%
May 9 BRIEF-BeiGene Q1 Loss Per Share $0.22
May 9 BeiGene beats by $0.81, beats on revenue
May 9 BeiGene Reports First Quarter 2019 Financial Results
May 8 Notable earnings after Thursday’s close
May 8 BeiGene Q1 2019 Earnings Preview
May 6 SpringWorks teams up with Beigene in cancer study
See more BGNE news...
Indicators
Indicator Value
52 Week High 220.1
52 Week Low 105.19
Average Volume 294,625
200-Day Moving Average 140.5115
50-Day Moving Average 131.0116
20-Day Moving Average 126.1695
10-Day Moving Average 128.463
Average True Range 6.9713
ADX 19.43
+DI 27.6472
-DI 18.087
Chandelier Exit (Long, 3 ATRs ) 118.3561
Chandelier Exit (Short, 3 ATRs ) 136.1939
Upper Bollinger Band 137.5562
Lower Bollinger Band 114.7828
Percent B (%b) 0.73
BandWidth 18.049846
MACD Line 0.4769
MACD Signal Line -1.0523
MACD Histogram 1.5292
Fundamentals Value
Market Cap 5.24 Billion
Num Shares 39.8 Million
EPS -4.97
Price-to-Earnings (P/E) Ratio -26.46
Price-to-Sales 0.00
Price-to-Book 12.46
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 140.81
Resistance 3 (R3) 141.69 139.48 139.25
Resistance 2 (R2) 139.48 137.10 139.03 138.73
Resistance 1 (R1) 135.48 135.64 134.38 134.60 138.22
Pivot Point 133.27 133.27 132.71 132.82 133.27
Support 1 (S1) 129.27 130.89 128.17 128.39 124.76
Support 2 (S2) 127.06 129.43 126.61 124.25
Support 3 (S3) 123.06 127.06 123.73
Support 4 (S4) 122.18